TABLE 1.
Basic characteristics of included studies.
| Study | Sample (E/C) | Gender (M/F) | Age (years) | Intervention | Study period | Outcomes |
|---|---|---|---|---|---|---|
| Sun et al. (2012) | 33/31 | 33/31 | – | E: RDN+CT | 7–10 | ①⑦⑧ |
| C: CT | ||||||
| Yin et al. (2013) | 40/40 | E: 25/15 | E: 45.6±8.1 | E: RDN+CT | 10 | ①②③④⑤ |
| C: 30/10 | C: 50.6±6.9 | C: CT | ||||
| Liu and Liu (2014) | 34/36 | E: 20/14 | E: 35.42±1.66 | E: RDN+CT+AB | 12 | ①②④⑤⑥ |
| C: 18/18 | C: 36.32±1.56 | C: CT+AB | ||||
| Li (2014) | 68/72 | E: 40/28 | E: 34.22±1.77 | E: RDN+CT+AB | 12 | ①②④⑤⑥ |
| C: 36/36 | C: 35.22±1.66 | C: CT+AB | ||||
| Lin (2015) | 36/30 | – | – | E: RDN+CT+Ig | 5 | ②③④⑤⑧ |
| C: CT+Ig | ||||||
| Zhang et al. (2016) | 43/43 | E: 25/18 | E: 63.29±9.03 | E: RDN+CT | 7–10 | ①⑧ |
| C: 23/20 | C: 62.86±8.85 | C: CT | ||||
| Nie (2017) | 42/42 | E: 22/20 | E: 51.33±5.73 | E: RDN+CT | 3 | ①⑧ |
| C: 24/18 | C: 52.10±5.68 | C: CT | ||||
| Zhou (2017) | 39/39 | E: 20/19 | E: 73.54±12.09 | E: RDN+CT | 14 | ①②⑤ |
| C: 22/17 | C: 72.68±11.26 | C: CT | ||||
| Ding (2017) | 50/50 | E: 29/21 | E: 71.37±5.71 | E: RDN+CT | 10 | ①②③④⑤ |
| C: 31/19 | C: 71.54±5.69 | C: CT | ||||
| Fang et al. (2018) | 36/36 | E: 21/15 | E: 34.1±3.2 | E: RDN+CT+AB | 12 | ①②④⑤⑥⑧ |
| C: 22/14 | C: 33.8±2.7 | C: CT+AB | ||||
| Chen (2018) | 48/48 | E: 29/19 | – | E: RDN+CT+PI | 7 | ①⑧ |
| C: 30/18 | C: CT | |||||
| Zhu et al. (2019) | 43/43 | E: 24/19 | E: 37.82±6.09 | RDN+CT | 14 | ①②③④⑥ |
| C: 23/20 | C: 37.51±6.23 | C: CT | ||||
| Tan et al. (2019) | 52/51 | E: 28/24 | E: 63.52±7.01 | E: RDN+CT+BAL | 7 | ①⑦⑧ |
| C: 28/23 | C: 64.01±6.87 | C: CT+BAL | ||||
| Yan et al. (2019) | 42/42 | E: 28/14 | E: 56.10±8.23 | E: RDN+AB | 7 | ①②③④⑥ |
| C: 24/18 | C: 56.02±8.37 | C: AB | ||||
| Shan (2020) | 50/50 | E: 29/21 | E: 57.5±5.8 | E: RDN+AB | 7 | ①②③④ |
| C: 28/22 | C: 57.9±6.1 | C: AB | ||||
| Wang et al. (2020) | 30/30 | E: 16/14 | E: 59.97±4.03 | E: RDN+CT | 7 | ①⑦ |
| C: 15/15 | C: 61.03±4.07 | C: CT | ||||
| Bai and Xu (2021) | 32/32 | – | E: 55.17±7.55 | E: RDN+AB | 7 | ① |
| C: 55.28±7.49 | C: AB | |||||
| Pan (2022) | 40/40 | E: 26/14 | E: 56.29±4.34 | E: RDN+CT+AB | 12 | ①②④⑤⑥ |
| C: 27/13 | C: 57.13±3.68 | C: CT+AB | ||||
| Guo and Huo (2022) | 57/57 | E: 34/23 | E: 34.42±1.98 | E: RDN+CT+AB | 12 | ①②④⑤⑥⑧ |
| C: – | C: 33.85±2.05 | C: CT+AB | ||||
| Li and Shao (2022) | 43/43 | E: 28/15 | E: 37.82±6.90 | E: RDN+AB | 14 | ①②③④⑤⑥⑦⑧ |
| C: 26/17 | C: 37.16±6.51 | C: AB | ||||
| Xing and Lin (2022) | 45/45 | E: 27/18 | E: 57.93±3.54 | E: RDN+AB | 5 | ②③④⑧ |
| C: 26/19 | C: 57.89±3.57 | C: AB | ||||
| Wang et al. (2023) | 47/47 | E: 30/17 | E: 53.20±5.68 | E: RDN+AB | 10 | ①②③④⑧ |
| C: 28/19 | C: 53.04±5.42 | C: AB |
Abbreviations: E, experimental group; C, control group; AB, antibiotics; CT, conventional therapy; Ig, immunoglobulin; PI, protease inhibitor; BAL, bronchoalveolar lavage; RDN, Reduning. ① Clinical efficacy; ② Time for defervescence; ③ Time for disappearance of cough; ④ Time for disappearance of lung rales; ⑤ Improvement time of chest X-ray; ⑥ The hospitalization time; ⑦ Acute Physiology and Chronic Health Evaluation (APACHE Ⅱ); ⑧Adverse reactions.